Journal Report

CANCER TREATMENT REVIEWS

Download PDF
Journal Information
Journal Title
CANCER TREATMENT REVIEWS
Publisher
ELSEVIER SCI LTD
ISSN
0305-7372
E-ISSN
1532-1967
Database
Clarivate
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Artificial intelligence–enabled drug discovery: A growing but largely early-stage clinical pipeline
Waqas Haque, Kareena Sai-Palm, Iemaan Rana et al.
2026-12 Vol. 151 Pages 103223
DOI: 10.1016/j.ctrv.2026.103223
T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
May-Lucie Meyer, Solange Peters, Myung-Ju Ahn et al.
2026-12 Vol. 151 Pages 103201
DOI: 10.1016/j.ctrv.2026.103201
The prognostic value of pathological response in soft tissue sarcoma: A systematic review
Bauke H.G. van Riet, Stijn J.C. van der Burg, Tom van der Klaauw et al.
2026-12 Vol. 151 Pages 103219
DOI: 10.1016/j.ctrv.2026.103219
Systemic therapy for metastatic nasopharyngeal carcinoma in the immunotherapy era: A critical review
Weijie Wen, Jishi Li, Yuan Qu et al.
2026-12 Vol. 151 Pages 103214
DOI: 10.1016/j.ctrv.2026.103214
CDH1 germline carriers and diffuse gastric Cancer: Are we ready for personalized surveillance and prevention?
Mara Cruellas, Joaquín Castillo-Iturra, Tian V. Tian et al.
2026-12 Vol. 151 Pages 103225
DOI: 10.1016/j.ctrv.2026.103225
Incidence and severity of nausea and vomiting with trastuzumab deruxtecan: a systematic review and meta-analysis
J. Leigh, C.F. Theriau, B. Alshamsan et al.
2026-12 Vol. 151 Pages 103239
DOI: 10.1016/j.ctrv.2026.103239
Immune checkpoint inhibitors in platinum-resistant ovarian cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities
Elena Giudice, Andrea Spinazzola, Charalampos S. Floudas et al.
2026-12 Vol. 151 Pages 103237
DOI: 10.1016/j.ctrv.2026.103237
Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma
María José Juan Fita, Urbano Anido, Luis Bataller et al.
2026-12 Vol. 151 Pages 103233
DOI: 10.1016/j.ctrv.2026.103233
Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression
Francesca Piazza, Rishi Sharma, Alessandra Esposito et al.
2026-12 Vol. 151 Pages 103235
DOI: 10.1016/j.ctrv.2026.103235
Exercise as anticancer medicine? Evidence, mechanisms and implementation in oncology
Manuela Schmidinger, Irene Huebner-Resch, Shahrokh F. Shariat
2026-12 Vol. 151 Pages 103222
DOI: 10.1016/j.ctrv.2026.103222
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: October 31, 2026 12:57